News brief­ing: Tiny Vac­cinex's drug flops in PhII Hunt­ing­ton's tri­al, stock craters; Siol­ta nabs $30M Se­ries B to de­vel­op mi­cro­bio­me drug

Siol­ta Ther­a­peu­tics, a mi­cro­bio­me com­pa­ny tar­get­ing al­ler­gic dis­eases, raked in a $30 mil­lion Se­ries B to de­vel­op its lead can­di­date, STMC-103H. The drug, which has been FDA fast-tracked, is head­ed for proof-of-con­cept tri­als, ac­cord­ing to the com­pa­ny. Its var­i­ous in­di­ca­tions in­clude al­ler­gic asth­ma, food al­ler­gies, atopic der­mati­tis, al­ler­gic rhini­tis, and al­ler­gy pre­ven­tion.

The news comes just af­ter the Cal­i­for­nia-based biotech added a promi­nent bio­phar­ma vet­er­an as an ad­vi­sor: 20-year Gilead CEO John Mar­tin. The biotech al­so gained Richard Shames as CMO, who came by way of Pro­tag­o­nist Ther­a­peu­tics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.